Malignant Lymphomas

Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases

CD4+/CD56+ hematodermic neoplasm (WHO-EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+/CD56− lin skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present five cases to highlight the need for greater awareness of this entity amongst pathologists such that aggressive treatment be considered given the generally poor prognosis.

Haematologica 2006; 91:143-144 (http://www.haematologica.org/journal/2006/01/143.html)

Recently classified as CD4+/CD56− hematodermic neoplasm1 (WHO-EORTC), the aggressive CD4+/CD56− NK blastic lymphoma (WHO) included within the CD30 negative cutaneous lymphomas (EORTC) was believed to derive from natural killer (NK) cells. Evidence now suggests, however, an early plasmacytoid type 2 dendritic cell (DC2) origin.2,3 Cases characteristically demonstrate a CD4+CD56− lineage-negative immunophenotype and unlike NK-nasal and nasal-type lymphoma, absence of detectable Epstein-Barr virus (EBV) genome.4,6 Primarily affecting elderly adults5,6 and often confined to the skin at presentation,5 progression to more generalized hematodermic neoplasm (WHO-EORTC), the aggressive CD4+CD56− lin skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present five cases to highlight the need for greater awareness of this entity amongst pathologists such that aggressive treatment be considered given the generally poor prognosis.

We describe our experience in managing five new cases of CD4+/CD56− hematodermic neoplasm referred to our Institute between 1997 and 2003. Five males (median age 74 years, range 63-90) (Table 1) presented with solitary or multicentric cutaneous lesions on the scalp, trunk or extremities. These lesions were erythematous or hyperpigmented nodules. Comprehensive staging demonstrated skin-limited disease in all cases. All cases received an amended pathological diagnosis on review. Skin biopsies demonstrated a lymphoid infiltrate involving the dermis and subcutis but sparing the epidermis (Figures 1A and B). Cytologically, the malignant cells appeared as abnormal medium-sized lymphoid cells with an absence of cytoplasmic azurophilic granules (Figure 1B). Angiocentricity and necrosis were not noted. Immunohistochemical staining demonstrated a CD3 and CD20 negative malignant cell population in all cases. CD4 staining was positive in four of the remaining case demonstrating CD4 positive cells on peripheral blood flow cytometric analysis at relapse. CD43 was positive in the four of five cases tested. Epstein-Barr virus in situ hybridization on skin biopsy specimens was negative in all cases. Molecular studies demonstrated polyclonal T-cell receptor gene rearrangement in all four cases tested (Table 1). Flow cytometric analysis of bone marrow aspirate and/or peripheral blood at relapse in two patients demonstrated a CD4+, CD56− and CD45 positive population of malignant cells, which were CD3+, B-cell antigen and myeloid antigen negative (Table 1). Three patients treated with front-line combination chemotherapy, two with CHOP and one with Rituxan, achieved complete remission, with two patients alive at last follow-up.

Table 1. Summary of cases CD4+/CD56− hematodermic neoplasm.

<table>
<thead>
<tr>
<th>Case/Sex/ Age (y)</th>
<th>Skin lesions at presentation</th>
<th>Initial Diagnosis (immunohistochemical and molecular characteristics)</th>
<th>Initial treatment</th>
<th>Relapse</th>
<th>Immunohistochemical and molecular features at relapse</th>
<th>Time to relapse (months)</th>
<th>Outcome and survival from diagnosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/Male/ 90</td>
<td>Solitary red oval nodules left forearm</td>
<td>CD30− CTLD</td>
<td>Topical steroid, radiotherapy</td>
<td>CCR</td>
<td>Skin, lymph node, peripheral blood, bone marrow</td>
<td>15</td>
<td>Died, Progressive disease, 22</td>
</tr>
<tr>
<td>2/Male/ 63</td>
<td>Multicentric red nodules left scalp and satellite nodules</td>
<td>CD30− CTL</td>
<td>CHOPD</td>
<td>CCR</td>
<td>NA</td>
<td>NA</td>
<td>Alive, 27</td>
</tr>
<tr>
<td>3/Male/ 74</td>
<td>Multicentric nodules back, forehead, legs</td>
<td>CD30− CTL</td>
<td>Chlorambucil, Radiotherapy</td>
<td>PR</td>
<td>Skin, lymph node, bone marrow, central nervous system</td>
<td>1</td>
<td>Died, Post surgical complication, 12</td>
</tr>
<tr>
<td>4/Male/ 68</td>
<td>Multicentric nodules scalp, left leg, Plaque-like deposits abdomen</td>
<td>CD30− CTL</td>
<td>HyperCVADD</td>
<td>CCR</td>
<td>NA</td>
<td>NA</td>
<td>Alive, 38+</td>
</tr>
<tr>
<td>5/Male/ 75</td>
<td>Multicentric nodules right shoulder</td>
<td>CD30− CTL</td>
<td>CHOPD</td>
<td>CCR</td>
<td>Skin right thigh, skin right chest</td>
<td>17</td>
<td>Alive, 29+</td>
</tr>
</tbody>
</table>

1CD30 negative cutaneous T cell lymphoma; 2Epstein-Barr virus in situ hybridization; 3T-cell receptor gene rearrangement; 4polyclonal rearrangement; 5central nervous system prophylaxis with intrathecal methotrexate and intermediate dose systemic methotrexate was administered; 6clinical complete response defined as complete (100%) cutaneous remission; 7partial response defined as > 50% but < 100% improvement; 8additional antibodies; 9CD 2-7+ 19−; 10CD 2-19− 15− 33− 117+.

Letters to the Editor
HyperCVAD,6 achieved a clinical complete response and remain alive. Due to the risk of CNS relapse, prophylaxis with intrathecal chemo-prophylaxis and intermediate-dose systemic methotrexate was administered. One patient received consolidative radiotherapy to skin lesions. One patient relapsed with multicentric skin disease after 17 months of remission (Table 1). Two patients treated principally with local radiotherapy because of anticipated intolerance to systemic chemotherapy, relapsed, one after 15 months and the other after 1 month, with cutaneous lesions outside treated radiotherapy fields, lymphadenopathy, systemic symptoms and marrow involvement. Cerebrospinal fluid analysis showed that one patient had CNS involvement. Both patients died within 6 months of relapse, one from progressive disease and one from post-surgical complications following ommaya reservoir insertion.

CD4+/CD56+ hematodermic neoplasm accounts for 0.7% of cutaneous lymphomas.3 Survival is often short despite initial limited-stage disease and treatment with systemic chemotherapy.6 The newer EORTC-WHO classification differentiates CD4+/CD56+ hematodermic neoplasm from forms of extranodal lymphoma, leukemia cutis and acute leukemia. Characteristic but non-specific clinical, histological, immunophenotypic and molecular features are noted. Comprehensive clinical and pathological correlation may, potentially be assisted by newer immunological dendritic cell markers such as CD123,4 BDCA-2, BDCA-3 and BDCA-4 on flow cytometric analysis and TCL-1 and CLA on immunohistochemical staining. We recommend CD4 and CD56 immunohistochemistry be performed for cases of cutaneous lymphoma in which malignant cells are CD3 negative. Atypical features should also not exclude the diagnosis, as demonstrated by one patient in our series who was CD4 negative on skin biopsy immunohistochemistry and CD4 positive on flow cytometry at relapse.

Leukemic variants should be suspected on flow cytometric analysis if gated blasts are negative for myeloperoxidase and TdT and by a CD4+CD56lin-phenotype. CD123 may be a useful affirmative marker. Cytogenetic aberrations are not diagnostic.3 Although optimal therapy remains unknown and delivery of aggressive therapy is often limited by advanced age and co-morbidities, our series suggests systemic chemotherapy should be considered in appropriate patients, since this strategy produced two remissions lasting over 2 years. One of these patients, a recipient of HyperCVAD, remains disease-free at 38 months. The role of allogeneic transplantation remains to be defined.

Accurate pathological diagnosis of CD4+/CD56+ hematodermic neoplasm is essential for prognosis and treatment. Previous EORTC and WHO classifications of cutaneous lymphomas fail to clearly differentiate this entity and it is therefore recommended that the recently published WHO-EORTC classification of cutaneous lymphoma is adopted.

Ashley P Ng,* Stephen Lade,* Timothy Rutherford,* H Miles Prince,* David A Westerner*


Acknowledgements: Dr. John Scarlett for his assistance in ongoing patient care.

Key words: cutaneous lymphoma, hematodermic, NK blastic.

Correspondence: H Miles Prince, Chair, Haematology Service, Director, Blood and Marrow Transplant Program, Peter MacCallum Cancer Centre, Locked Bag 1, A-Beckett St, Melbourne 8000, Australia. Phone: international +61-3.96561700. Fax: international +61-3.96561408. E-mail: miles.prince@petermac.org

| 144 | haematologica/the hematology journal | 2006: 91(1) |